The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models

International Journal of Oncology

Volumn 46, Issue 6, 2015, Pages 2335-2345

  Garona, Juan ^a   Pifano, Marina ^a   Orlando, Ulises D ^b   Pastrian, Maria B ^b   Ianuci, Nancy B ^b   Ortega, Hugo H ^c   Podesta, Ernesto J ^b   Gomez, Daniel E ^a   Ripol, Gisele V ^a   Alonso, Daniel F ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

Breast carcinoma; Desmopressin analogue; Metastases; Tumour vascularisation; Vasopressin type 2 receptor; V4Q5 dDAVP

Indexed keywords

1 DEAMINO 4 VALINE 5 GLUTAMINE 8 DEXTRO ARGININE VASOPRESSIN; ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; DESMOPRESSIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASOPRESSIN V2 RECEPTOR; ARGININE VASOPRESSIN RECEPTOR 2, HUMAN; ARGIPRESSIN[1 DEAMINO]; DESMOPRESSIN, VALYL(4)-GLUTAMINYL(5)-; VASOPRESSIN RECEPTOR;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION ASSAY; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; CYTOSTASIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MCF 7 CELL LINE; MDA MB 231 CELL LINE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; MCF-7 CELL LINE; METABOLISM; METASTASIS; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEAMINO ARGININE VASOPRESSIN; FEMALE; HUMANS; MCF-7 CELLS; MICE; NEOPLASM METASTASIS; RECEPTORS, VASOPRESSIN; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928540738     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2952     Document Type: Article

References (53)

1. Vande Walle J, Stockner M, Raes A and Nørgaard JP: Desmopressin 30 years in clinical use: A safety review. Curr Drug Saf 2: 232-238, 2007.
2. Manning M, Stoev S, Chini B, Durroux T, Mouillac B and Guillon G: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: Research tools and potential therapeutic agents. Prog Brain Res 170: 473-512, 2008.
3. Kaufmann JE and Vischer UM: Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 1: 682-689, 2003.
4. Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 90: 2515-2521, 1997.
5. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M and Guillon G: Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 24: 609-628, 2012.
6. North WG, Fay MJ and Du J: MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20: 837-842, 1999.
7. Petit T, Davidson KK, Lawrence RA, von Hoff DD and Izbicka E: Neuropeptide receptor status in human tumor cell lines. Anticancer Drugs 12: 133-136, 2001.
8. Taylor AH, Ang VT, Jenkins JS, Silverlight JJ, Coombes RC and Luqmani YA: Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 50: 7882-7886, 1990.
9. Alonso DF, Skilton G, Farías EF, Bal de Kier Joffé E and Gomez DE: Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat 57: 271-275, 1999.
10. Garona J, Pifano M, Scursoni AM, Gomez DE, Alonso DF and Ripoll GV: Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. Anticancer Res 34: 4761-4765, 2014.
11. Giron S, Tejera AM, Ripoll GV, Gomez DE and Alonso DF: Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. J Surg Oncol 81: 38-44, 2002.
12. Hermo GA, Torres P, Ripoll GV, Scursoni AM, Gomez DE, Alonso DF and Gobello C: Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. Vet J 178: 103-108, 2008.
13. Hermo GA, Turic E, Angelico D, Scursoni AM, Gomez DE, Gobello C and Alonso DF: Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade. J Am Anim Hosp Assoc 47: 21-27, 2011.
14. Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ and Denis CV: Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 4: 519-526, 2006.
15. Ripoll GV, Garona J, Pifano M, Farina HG, Gomez DE and Alonso DF: Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. Breast Cancer Res Treat 142: 9-18, 2013.
16. Sakurai T and Kudo M: Signaling pathways governing tumor angiogenesis. Oncology 81 (Suppl 1): 24-29, 2011.
17. Westphal JR, Van't Hullenaar R, Geurts-Moespot A, Sweep FC, Verheijen JH, Bussemakers MM, Askaa J, Clemmensen I, Eggermont AA, Ruiter DJ, et al: Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 86: 760-767, 2000.
18. Alonso DF, Ripoll GV, Garona J, Iannucci NB and Gomez DE: Metastasis: Recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol 12: 1974-1980, 2011.
19. Czaplewski C, Kaźmierkiewicz R and Ciarkowski J: Molecular modeling of the human vasopressin V2 receptor/agonist complex. J Comput Aided Mol Des 12: 275-287, 1998.
20. Czaplewski C, Kaźmierkiewicz R and Ciarkowski J: Molecular modelling of the vasopressin V2 receptor/antagonist interactions. Acta Biochim Pol 45: 19-26, 1998.
21. Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE and Alonso DF: Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. Future Med Chem 3: 1987-1993, 2011.
22. Pastrian MB, Guzmán F, Garona J, Pifano M, Ripoll GV, Cascone O, Ciccia GN, Albericio F, Gómez DE, Alonso DF, et al: Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. Mol Med Rep 9: 2568-2572, 2014.
23. Holliday DL and Speirs V: Choosing the right cell line for breast cancer research. Breast Cancer Res 13: 215, 2011.
24. Ripoll GV, Giron S, Krzymuski MJ, Hermo GA, Gomez DE and Alonso DF: Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. Anticancer Res 28A: 2607-2611, 2008.
25. Cardama GA, Comin MJ, Hornos L, Gonzalez N, Defelipe L, Turjanski AG, Alonso DF, Gomez DE and Menna PL: Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med Chem 14: 840-851, 2014.
26. Jones LW, Eves ND, Courneya KS, Chiu BK, Baracos VE, Hanson J, Johnson L and Mackey JR: Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clin Cancer Res 11: 6695-6698, 2005.
27. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W and Vischer UM: Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 106: 107-116, 2000.
28. Han SS, Cho CK, Lee YW and Yoo HS: Antimetastatic and immunomodulating effect of water extracts from various mushrooms. J Acupunct Meridian Stud 2: 218-227, 2009.
29. North WG, Pai S, Friedmann A, Yu X, Fay M and Memoli V: Vasopressin gene related products are markers of human breast cancer. Breast Cancer Res Treat 34: 229-235, 1995.
30. Keegan BP, Akerman BL, Péqueux C and North WG: Provasopressin expression by breast cancer cells: Implications for growth and novel treatment strategies. Breast Cancer Res Treat 95: 265-277, 2006.
31. Carie AE and Sebti SM: A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 26: 3777-3788, 2007.
32. Insel PA, Zhang L, Murray F, Yokouchi H and Zambon AC: Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf) 204: 277-287, 2012.
33. Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M, Caraglia M, Chiosi E, et al: Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther 8: 1183-1190, 2009.
34. Castoria G, Migliaccio A, D'Amato L, Di Stasio R, Ciociola A, Lombardi M, Bilancio A, Di Domenico M, De Falco A and Auricchio F: Integrating signals between cAMP and MAPK pathways in breast cancer. Front Biosci 13: 1318-1327, 2008.
35. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer - current status and future directions. Ann Oncol 20: 1913-1927, 2009.
36. Bayraktar S and Glück S: Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 138: 21-35, 2013.
37. Terrenato I, Arena V, Pizzamiglio S, Pennacchia I, Perracchio L, Buglioni S, Ercolani C, Sperati F, Costarelli L, Bonanno E, et al: External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: An experience on a regional scale. J Exp Clin Cancer Res 32: 58, 2013.
38. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, et al: Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46: 1866-1871, 2005.
39. Ripoll G, Iannucci N, Giron S, Cascone O, Gomez D and Alonso D: Angiostatic activity of 1-Deamino-8-D-Arginine vasopressin and novel peptide analogues in breast cancer cells. Proc AACR, Abst 295, 2008.
40. Huang J, Roth R, Heuser JE and Sadler JE: Integrin alpha(v) beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood 113: 1589-1597, 2009.
41. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, et al: Endothelial von Willebrand factor regulates angiogenesis. Blood 117: 1071-1080, 2011.
42. Howe AK: Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta 1692: 159-174, 2004.
43. Howe AK, Baldor LC and Hogan BP: Spatial regulation of the cAMP-dependent protein kinase during chemotactic cell migration. Proc Natl Acad Sci USA 102: 14320-14325, 2005.
44. Kim S, Harris M and Varner JA: Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem 275: 33920-33928, 2000.
45. Terraube V, Marx I and Denis CV: Role of von Willebrand factor in tumor metastasis. Thromb Res 120 (Suppl 2): S64-S70, 2007.
46. Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst 104: 906-922, 2012.
47. Erdélyi LS, Balla A, Patócs A, Tóth M, Várnai P and Hunyady L: Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus. Mol Endocrinol 28: 634-643, 2014.
48. Liu H, Gaza-Bulseco G and Chumsae C: Glutamine deamidation of a recombinant monoclonal antibody. Rapid Commun Mass Spectrom 22: 4081-4088, 2008.
49. Robinson AB and Rudd CJ: Deamidation of glutaminyl and asparaginyl residues in peptides and proteins. Curr Top Cell Regul 8: 247-295, 1974.
50. Lianos GD, Vlachos K, Zoras O, Katsios C, Cho WC and Roukos DH: Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther 7: 491-500, 2014.
51. Bacic I, Druzijanic N, Karlo R, Skific I and Jagic S: Efficacy of IP6 inositol in the treatment of breast cancer patients receiving chemotherapy: Prospective, randomized, pilot clinical study. J Exp Clin Cancer Res 29: 12, 2010.
52. Fabbrocini G, Cameli N, Romano MC, Mariano M, Panariello L, Bianca D and Monfrecola G: Chemotherapy and skin reactions. J Exp Clin Cancer Res 31: 50, 2012.
53. Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, Billet S, Fernandez A, Bhowmick NA, et al: Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res 19: 128-137, 2013.